Symptoms that linger after Lyme disease: what the antibiotic trials found
How often fatigue, pain, and thinking problems continue after treated Lyme disease, what four placebo-controlled trials of longer antibiotic courses showed, and what researchers are studying now.

About 476,000 people a year are diagnosed with and treated for Lyme disease in the United States, according to an analysis of insurance claims (Kugeler et al., 2021). Most recover after a course of antibiotics. Some continue to have fatigue, body aches, or difficulty thinking for months afterward. The Centers for Disease Control and Prevention calls this post-treatment Lyme disease syndrome and says its cause is not known (Centers for Disease Control and Prevention).
This article is for people who were treated for Lyme disease and still do not feel well, and want to know what studies have found about how common this is and what helps.
Lyme disease and its standard treatment
Lyme disease is caused by bacteria carried by blacklegged ticks. The first sign is usually an expanding red rash at the site of the bite, often with fever, headache, and fatigue. If the infection is not treated it can spread to the joints, the heart, and the nervous system. A course of oral antibiotics, most often doxycycline, is the standard treatment for early disease (Lantos et al., 2021).
How common it is
The answer depends on how the question is asked, because fatigue and aches are also common in people who have never had Lyme disease.
A Dutch study followed 1,084 treated patients and two comparison groups for a year. Persistent symptoms were found in 27.2 percent of the Lyme patients, 21.2 percent of people from the general population, and 23.3 percent of people who had a tick bite without Lyme disease. The share that can be attributed to the infection was therefore about 4 to 6 percentage points (Ursinus et al., 2021).
A U.S. study followed people who had been diagnosed and treated promptly. Of those with Lyme disease, 13.7 percent met a research definition of the syndrome, compared with 4.1 percent of a comparison group (Aucott et al., 2022).
In that study the risk was higher in women and in people who had been through more traumatic life events. People who had had Lyme disease were also far more likely than the comparison group to report moderate or severe fatigue and muscle pain (Aucott et al., 2022).
For the people affected, the symptoms can be severe. In a study of patients who met the research definition, scores for fatigue, pain, and sleep were far worse than in healthy controls, and their physical quality-of-life score averaged 33.9, compared with 55.1 in the controls (Rebman et al., 2017).
Four trials of longer antibiotic treatment
If lingering infection were the cause, more antibiotics should help. Four placebo-controlled trials have tested this.
The first, published in 2001, enrolled 129 patients. They received either a month of intravenous ceftriaxone followed by two months of oral doxycycline, or matching placebos. The trials were stopped early when an interim analysis showed that a difference between the groups was highly unlikely. There were no significant differences in quality of life. At the start of the trials, the patients' quality of life was severely impaired, which shows how unwell this group can be (Klempner et al., 2001).
The second gave 55 patients with severe fatigue either 28 days of intravenous ceftriaxone or placebo. Fatigue improved more in the antibiotic group, but mental speed did not. Four patients had adverse events that required a hospital stay, three of them in the placebo group, which shows that an intravenous line carries risk in its own right. The authors concluded that the results did not support using this treatment (Krupp et al., 2003).
The third studied 37 patients with memory problems, who received ten weeks of intravenous ceftriaxone or placebo. Thinking improved at 12 weeks in the antibiotic group, but the improvement was gone at 24 weeks. About a quarter of those given the antibiotic had adverse events from the drug or the intravenous line (Fallon et al., 2008).
The fourth and largest, in the Netherlands, gave all 280 patients two weeks of intravenous ceftriaxone and then 12 weeks of doxycycline, a combination of clarithromycin and hydroxychloroquine, or placebo. Quality-of-life scores at the end of treatment were nearly identical in the three groups (Berende et al., 2016).
On this evidence, a joint guideline from three U.S. medical societies recommends against further antibiotics for people who have ongoing nonspecific symptoms after standard treatment and no objective sign of active infection (Lantos et al., 2021). Long courses also carry risks. A CDC report described septic shock, bone infection, severe colitis, and abscesses in patients given prolonged intravenous treatment for what was called chronic Lyme disease (Marzec et al., 2017).
What might explain the symptoms
The cause is unknown, and the CDC points out that similar prolonged symptoms occur after other kinds of infection (Centers for Disease Control and Prevention). Researchers are looking at several possibilities.
One is that pieces of the bacteria remain after the bacteria themselves are dead. In patients with Lyme arthritis, a separate complication that affects the joints, fragments of the bacterial cell wall were found in joint fluid after antibiotic treatment and were able to provoke inflammation (Jutras et al., 2019). Whether something similar happens in people with fatigue and pain is not known.
Another is a lasting change in the brain's immune cells. A pilot study using PET scans found higher levels of a marker of activated immune cells across eight brain regions in 12 patients with post-treatment symptoms than in 19 healthy controls (Coughlin et al., 2018). The study was small and needs to be repeated.
What the trials do and do not show
None of the four trials found a lasting benefit. They tested one idea, that the symptoms come from surviving bacteria that more antibiotics could clear. They do not show that the symptoms are imagined or that nothing can help.
The CDC states that there is a critical need to understand the causes of prolonged symptoms after Lyme disease and the best approaches to treatment and care (Centers for Disease Control and Prevention). Current research is looking at the immune system and the nervous system, and at treatments aimed at the symptoms themselves.
Practical points
- Most people improve with time. The CDC says patients usually get better without additional antibiotics, although it can take many months (Centers for Disease Control and Prevention).
- Ask your doctor to look for other explanations, including thyroid disease, anemia, sleep apnea, depression, and other infections carried by ticks.
- Treat the symptoms you have. Approaches used for chronic fatigue, such as pacing activity and improving sleep, may help.
- Be cautious about long-term antibiotics and about tests or treatments that are not part of standard care.
- A new rash, a swollen joint, or facial weakness is different from lingering symptoms and should be checked, because a new tick bite can cause a new infection.
When to see a doctor
See a doctor if symptoms have not started to improve several months after treatment or if they are getting worse. Seek care promptly for chest pain, palpitations, fainting, facial drooping, severe headache with a stiff neck, or a swollen, painful joint.
Sources
- Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010-2018 (Kugeler et al., Emerging Infectious Diseases, 2021) — analysis of commercial insurance claims, 2010 to 2018
- Chronic Symptoms and Lyme Disease (Centers for Disease Control and Prevention) — U.S. government guidance on prolonged symptoms after Lyme disease
- Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease (Lantos et al., Clinical Infectious Diseases, 2021) — clinical practice guideline from three U.S. medical societies
- Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study (Ursinus et al., The Lancet Regional Health Europe, 2021) — prospective cohort study in the Netherlands, 1,084 patients and two comparison groups
- Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: A prospective cohort study (Aucott et al., International Journal of Infectious Diseases, 2022) — prospective cohort study, 234 participants with prior Lyme disease and 49 without
- The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome (Rebman et al., Frontiers in Medicine, 2017) — case-control study of patients meeting a research definition of the syndrome
- Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease (Klempner et al., New England Journal of Medicine, 2001) — two randomized placebo-controlled trials, 129 patients enrolled
- Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial (Krupp et al., Neurology, 2003) — randomized placebo-controlled trial, n=55
- A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy (Fallon et al., Neurology, 2008) — randomized placebo-controlled trial, 37 patients
- Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease (Berende et al., New England Journal of Medicine, 2016) — randomized placebo-controlled trial, n=280
- Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease - United States (Marzec et al., Morbidity and Mortality Weekly Report, 2017) — CDC case reports
- Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis (Jutras et al., Proceedings of the National Academy of Sciences, 2019) — laboratory study of joint fluid from patients with Lyme arthritis
- Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [(11)C]DPA-713 PET (Coughlin et al., Journal of Neuroinflammation, 2018) — pilot brain imaging study, 12 patients and 19 controls
This article is for general information and is not medical advice. Talk to your doctor before changing a medication, treatment or exercise program.



